Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Differences between CML in children and adults & the potential of asciminib in pediatric patients

Nobuko Hijiya • 6 Jun 2023
EHA 2023
Chronic Myeloid Leukemia Leukemia Asciminib Imatinib

Nobuko Hijiya, MD, Columbia University Irving Medical Center, New York City, NY, comments on the key differences in the biology of chronic myeloid leukemia (CML) in children and adults, and highlights the need for new treatment strategies in children, such as asciminib, which has a better tolerability profile than other tyrosine kinase inhibitors (TKIs) and may increase the likelihood of patients achieving treatment-free remission (TFR). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nobuko Hijiya

1:49
ASC4KIDS: investigating asciminib for pediatric patients with CML
Nobuko Hijiya • 6 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals